Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Laux

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Vascular Health and Risk Management|April 2, 2009
Emergence of new oral antithrombotics: a critical appraisal of their clinical potentialMichael Rud Lassen, Volker Laux
Journal of Cardiovascular Pharmacology and Therapeutics|April 8, 2015
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo StudiesElisabeth Perzborn, Stefan Heitmeier, Volker Laux
Thrombosis Research|June 7, 2020
The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant ratsMercedes López, Stefan Heitmeier, Volker Laux, et al.
Thrombosis Research|February 18, 2014
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitroElisabeth Perzborn, Stefan Heitmeier, Volker Laux, et al.
Seminars in Thrombosis and Hemostasis|July 17, 2007
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitorVolker Laux, Elisabeth Perzborn, Dagmar Kubitza, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
Approaches in anticoagulation: rationales for target positioningHeike A Wieland, Volker Laux, Detlef Kozian, et al.
Plos One|June 21, 2013
Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertensionKatrin F Nickel, Volker Laux, Rolf Heumann, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2010
Rivaroxaban: a new oral factor Xa inhibitorElisabeth Perzborn, Susanne Roehrig, Alexander Straub, et al.
Thrombosis Research|April 10, 2012
Similarities in thromboelastometric (ROTEM®) findings between humans and baboonsHerbert Schöchl, Cristina Solomon, Volker Laux, et al.
Journal of Medicinal Chemistry|April 29, 2005
Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functionsHans Matter, David W Will, Marc Nazaré, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Vascular Health and Risk Management|April 2, 2009
Emergence of new oral antithrombotics: a critical appraisal of their clinical potentialMichael Rud Lassen, Volker Laux
Journal of Cardiovascular Pharmacology and Therapeutics|April 8, 2015
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo StudiesElisabeth Perzborn, Stefan Heitmeier, Volker Laux
Thrombosis Research|June 7, 2020
The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant ratsMercedes López, Stefan Heitmeier, Volker Laux, et al.
Thrombosis Research|February 18, 2014
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitroElisabeth Perzborn, Stefan Heitmeier, Volker Laux, et al.
Seminars in Thrombosis and Hemostasis|July 17, 2007
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitorVolker Laux, Elisabeth Perzborn, Dagmar Kubitza, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
Approaches in anticoagulation: rationales for target positioningHeike A Wieland, Volker Laux, Detlef Kozian, et al.
Plos One|June 21, 2013
Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertensionKatrin F Nickel, Volker Laux, Rolf Heumann, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2010
Rivaroxaban: a new oral factor Xa inhibitorElisabeth Perzborn, Susanne Roehrig, Alexander Straub, et al.
Thrombosis Research|April 10, 2012
Similarities in thromboelastometric (ROTEM®) findings between humans and baboonsHerbert Schöchl, Cristina Solomon, Volker Laux, et al.
Journal of Medicinal Chemistry|April 29, 2005
Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functionsHans Matter, David W Will, Marc Nazaré, et al.
Pageof 4